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ened in the group receiving ceﬁxime (mean 15.0 hours vs
29.3 hours, p = 0.028). However, there was no signiﬁcant dif-
ference with respect to the rate of clearance of Salmonella
from stool (p = 0.843). All followed-up samples after com-
pleting therapy, remained sensitive in vitro to ceﬁxime.
There was no relapse of the same pathogen found.
Conclusion: The clinical trial showed that ceﬁxime could
shorten the time to defervescence and the duration of
diarrhea signiﬁcantly. Prolonging the period of carriage or
increasing the risk of relapse was not found in this study.
Ceﬁxime could be considered in acute, uncomplicated,
Salmonella enteritis in children with mucoid/bloody diar-
rhea.
doi:10.1016/j.ijid.2010.02.1923
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Evaluation of the pharmacodynamics of Daptomycin
(DAP)-Rifampin (RIF) combinations with Staphylococcus
aureus using various in vitro methods
S. Zinner1,∗, M. Smirnova2, E. Strukova2, A. Firsov2
1 Mount Auburn Hospital, Harvard Medical School, MA, MA,
USA
2 Gause Institute for Antibiotics, Moscow, Russian Federa-
tion
Background: The evaluation of antibiotic combinations
is often based on traditional checkerboard techniques (CT)
that might or might not provide optimal interpretations. In
this study, DAP plus RIF combinations were tested with S.
aureus using CT as well as time-kill curves at constant and
changing antibiotic concentrations – static studies (SS) and
dynamic studies (DS), respectively.
Methods: A clinical isolate S. aureus 866 (MIC of DAP
0.5mg/L, MIC of RIF 0.016mg/L) was tested using CT at DAP
concentrations ranging from 0 to 2mg/L and RIF concentra-
tions ranging from 0 to 0.06mg/L. In SS, the same organism
was exposed to DAP (0.5, 1, 2, 4, 8 and 6mg/L), alone and in
combination with RIF (DAP/RIF 1:1.5) over a 24-hour period.
In DS, S. aureus was exposed to daily administered DAP and
DAP+RIF for 5 consecutive days; the simulated ratios of area
under concentration-time curve (AUC) to the MIC were 50
and 50+75, respectively. The antimicrobial effects observed
in SS and DS were expressed by areas between the bacte-
rial concentration — time curves with and without antibiotic
(ABBCs).
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Results: Based on the CT data, DAP+RIF combinations
ere additive or indifferent (FIC index = 1). Based on ABBC
nalysis of the SS data, DAP+RIF was synergistic at relatively
ow AUC/MICs of DAP (24-96) or additive at higher AUC/MICs
f DAP (192-770). For example, the 24-hour ABBC of DAP
AUC/MIC 48) + RIF (AUC/MIC 72) was 9-fold greater than
hat of DAP (AUC/MIC 48). Similar differences in the effects
f DAP+RIF and DAP were established in DS: the 120-hour
BBC was 13 times greater in simulations of the combination
han DAP alone.
Conclusion: These data suggest that (1) checker-
oard technique-based evaluations of daptomycin+rifampin
ombinations can be misleading, and (2) in vitro pharmaco-
ynamic data obtained in static systems are predictive of
hose in dynamic studies.
oi:10.1016/j.ijid.2010.02.1924
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he effectiveness of oral suppression in high risk pros-
hetic joint infections after total knee arthroplasty
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Background: Prosthetic joint infection (PJI) is a rare but
erious complication of total knee arthroplasty (TKA) and is
frequent reason for failure to retain the prosthesis. Recent
tudies have reported success rates of >80 percent with
ebridement and retention of prosthesis between 2 to 5-year
ollow-up periods. Lack of consensus on deﬁnitions of PJI
nd risk factors between centers makes evaluation of true
isk factors and outcomes a challenge. Though improved suc-
ess rates have been reported for the conservative approach
f debridement, intravenous (IV) antimicrobial therapy, and
rosthesis retention, little data exists on combining the use
f oral suppressive therapy with this treatment option.
Methods: Nine year retrospective study of 28 high risk PJI
atients after TKA who had been treated with debridement,
ix weeks IV antimicrobial therapy and prosthesis retention,
r the same treatment with oral suppressive therapy and had
two to ﬁve year follow-up to ascertain the effectiveness
f oral suppressive therapy, excluding potential confound-
ng factors such as chemotherapy, HIV treatment, or steriod
herapy. Statististical analysis involved estimation of cumu-
ative probability of treatment failure using Kaplan Meier
ethod and total curve comparison was obtained by using
he Mantel-Cox logrank method. Fisher’s exact test and the
ilcoxon rank sum test were used for univariate analysis.
Results: The 2-year cumulative probability of failure for
ral suppressive therapy was 7% (95% CI: 0.04 to 27.5)
ompared to 42% (95% CI: 17.7 to 66.07) for the control
roup. Oral suppressive therapy was signiﬁcantly differ-
nt than control (P = 0.033).Conclusion: Treating high risk
atients with only six weeks IV antimicrobial therapy and
ebridement, especially in early postoperative infections,
ould lead to treatment failure sooner than when treating
atients with oral suppressive therapy. The effectiveness
f this treatment could reﬂect the importance of using
